MEDINCELL S.A. financials
MEDINCELL S.A.
Country: FR Reporting currency: EUR Latest annual report: 2025-03-31
LEI:
969500R79U6PXCL2FF46 Financial statements
(EUR, as reported — unscaled; 108 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €27.7M | €11.9M |
| Cost of sales | €0 | €0 |
| Other income | €2.3M | €2.9M |
| Distribution costs | €3.3M | €2.6M |
| Administrative expenses | €10.9M | €9.2M |
| Operating profit (EBIT) | -€10.8M | -€21.0M |
| Profit before tax | -€18.3M | -€24.9M |
| Income tax expense | €160.0K | €88.0K |
| Profit for the year | -€18.4M | -€25.0M |
| — attributable to owners | -€18.4M | -€25.0M |
| — attributable to NCI | €0 | €0 |
| Total comprehensive income | -€18.3M | -€24.9M |
| Per share | ||
| Basic EPS | €-0.62 | €-0.88 |
| Diluted EPS | €-0.62 | €-0.88 |
| Free cash flow / share | €0.63 | €-0.43 |
| Cash flow statement | ||
| Net cash from operating activities | €19.5M | -€11.9M |
| Net cash from investing activities | -€13.2M | -€613.0K |
| Purchase of PP&E (capex) | €747.0K | €324.0K |
| Purchase of intangibles | €913.0K | €867.0K |
| Net cash from financing activities | €33.3M | €25.5M |
| Proceeds from borrowings | €0 | €13.8M |
| Repayments of borrowings | €4.1M | €8.8M |
| Lease liability payments | €704.0K | €696.0K |
| Balance sheet | ||
| Total assets | €90.5M | €36.9M |
| Non-current assets | €9.8M | €9.7M |
| Property, plant & equipment | €2.3M | €2.3M |
| Right-of-use assets | €2.9M | €3.1M |
| Current assets | €80.6M | €27.3M |
| Trade & other receivables | €3.1M | €2.3M |
| Cash & equivalents | €59.0M | €19.5M |
| Total equity | -€16.4M | -€40.8M |
| — attributable to owners | -€16.4M | -€40.8M |
| Non-controlling interests | €0 | €0 |
| Non-current liabilities | €76.9M | €61.3M |
| Lease liabilities (non-current) | €2.0M | €2.3M |
| Current liabilities | €29.9M | €16.5M |
| Lease liabilities (current) | €673.0K | €643.0K |
| Trade & other payables | €4.0M | €1.8M |
| Derived metrics | ||
| Free cash flow | €18.7M | -€12.2M |
| Operating margin | -39.1% | -175.6% |
| Net margin | -66.5% | -209.6% |
| Return on equity | 112.7% | 61.3% |
| Cash conversion ratio | -1.06× | 0.48× |
| Capex coverage | 26.06× | -36.80× |
| Other reported items | ||
| Adjustments For Decrease Increase In Other Operating Receivables | -€44.0K | €5.1M |
| Adjustments For Decrease Increase In Trade Account Receivable | -€893.0K | -€161.0K |
| Adjustments For Depreciation and Amortisation Expense | €2.0M | €1.7M |
| Adjustments For Income Tax Expense | €160.0K | €88.0K |
| Adjustments For Increase Decrease In Other Operating Payables | €23.3M | €562.0K |
| Adjustments For Increase Decrease In Trade Account Payable | €2.1M | -€2.3M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €156.0K | €296.0K |
| Adjustments For Provisions | €1.1M | €997.0K |
| Adjustments For Reconcile Profit Loss | €13.5M | €10.0M |
| Adjustments For Sharebased Payments | €3.0M | €2.8M |
| Amount Removed From Reserve of Change In Value of Foreign Currency Basis Spreads and Included In Initial Cost Or Other Carrying Amount of Nonfinancial Asset Liability Or Firm Commitment For Which Fair Value Hedge Accounting Is Applied | -€1.0K | €0 |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | €0 |
| Comprehensive Income Attributable To Owners of Parent | -€18.3M | -€24.9M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €6.6M | €5.5M |
| Current Derivative Financial Liabilities | €0 | €0 |
| Current Provisions | €0 | €0 |
| Current Tax Assets Current | €0 | €0 |
| Current Tax Liabilities Current | €0 | €0 |
| Deferred Tax Assets | €0 | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €0 | €0 |
| Equity and Liabilities | €90.5M | €36.9M |
| Finance Income | -€7.4M | -€4.0M |
| Gains Losses On Exchange Differences On Translation Before Tax | €1.0K | €0 |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €0 | €0 |
| Income Taxes Paid Refund Classified As Operating Activities | €160.0K | €88.0K |
| Increase Decrease In Cash and Cash Equivalents | €39.6M | €13.0M |
| Increase Decrease In Number of Ordinary Shares Issued | 3.3M | 3.4M |
| Increase Decrease In Working Capital | -€24.5M | -€3.2M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €3.0M | €2.8M |
| Increase Decrease Through Treasury Share Transactions | €93.0K | -€25.0K |
| Intangible Assets Other Than Goodwill | €2.6M | €2.5M |
| Interest Income On Cash and Cash Equivalents | €1.4M | €553.0K |
| Interest Paid Classified As Financing Activities | €1.7M | €2.1M |
| Interest Received Classified As Investing Activities | €1.4M | €553.0K |
| Investment Accounted For Using Equity Method | €15.0K | €15.0K |
| Issue of Equity | €39.4M | €23.2M |
| Issued Capital | €331.0K | €291.0K |
| Losses On Change In Fair Value of Derivatives | €3.5M | €53.0K |
| Noncurrent Derivative Financial Liabilities | €8.6M | €5.7M |
| Noncurrent Provisions For Employee Benefits | €361.0K | €365.0K |
| Number of Shares Issued | 33.1M | 29.1M |
| Other Comprehensive Income | €95.0K | €90.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €94.0K | €90.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €94.0K | €90.0K |
| Other Current Financial Assets | €12.9M | €0 |
| Other Current Nonfinancial Assets | €5.6M | €5.5M |
| Other Current Nonfinancial Liabilities | €18.6M | €8.5M |
| Other Finance Cost | €230.0K | €1.0K |
| Other Finance Income | €0 | €145.0K |
| Other Inflows Outflows of Cash Classified As Investing Activities | -€91.0K | €24.0K |
| Other Longterm Provisions | €2.9M | €1.9M |
| Other Noncurrent Financial Assets | €1.9M | €1.8M |
| Other Noncurrent Financial Liabilities | €49.4M | €50.5M |
| Other Noncurrent Nonfinancial Liabilities | €13.7M | €492.0K |
| Payments To Acquire Or Redeem Entitys Shares | -€93.0K | €25.0K |
| Proceeds From Issuing Shares | €39.7M | €23.3M |
| Research and Development Expense | €24.3M | €21.1M |
| Reserve of Sharebased Payments | — | €298.0K |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€69.0M | -€47.1M |
| Retained Earnings Profit Loss For Reporting Period | -€18.4M | -€25.0M |
| Revenue From Contracts With Customers | €25.4M | €9.0M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €0 | €0 |
| Share Premium | €70.7M | €31.0M |
Methodology
Every line item above is a fact tagged in MEDINCELL S.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.